CLINICAL_TRIALS
trial_result
· 2019-06-26
Clinical Trial Update: A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma [Phase 1, Phase 2]
Summary
Phase I/II trial evaluating a peptide vaccine combined with ipilimumab in melanoma has terminated; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Craig L Slingluff, Jr | Conditions: Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-06-26